Navigation Links
Biomarkers May Aid in Early Diagnosis of Alzheimer's
Date:9/13/2010

By Jenifer Goodwin
HealthDay Reporter

MONDAY, Sept. 13 (HealthDay News) -- New research suggests that biomarkers in the blood may help diagnose Alzheimer's disease before it progresses, potentially opening the door to better treatments.

While there are currently no treatments that can halt or delay the onset of the disease, the hope is that being able to diagnose Alzheimer's earlier could provide clues about what medication might prevent it from getting worse, the study authors said.

"Most of the research to this point has been done on those who already have Alzheimer's disease," said study author Sid O'Bryant, director of research for the F. Marie Hall Institute for Rural and Community Health at Texas Tech University Health Sciences Center. "We need to be able to identify those at greatest risk."

In the study, researchers analyzed 100 biomarkers in the blood serum drawn from 197 patients with Alzheimer's and 203 people without Alzheimer's.

Participants were assigned a "risk score" based on levels of the various biomarkers, including C-reactive protein and interleukin-10, which have been associated with inflammation. About 22 of the 100 biomarkers emerged as the most significant, according to the study.

The biomarker risk score accurately identified 80 percent of those who had Alzheimer's disease. When Alzheimer's risk factors, such as age, sex, education and genetic information, were included, the test's accuracy was 94 percent.

Conversely, the biomarker risk score accurately identified who did not have the disease 91 percent of the time. When the other Alzheimer's risk factors were included in the score, accuracy was 84 percent.

The study is published in the September issue of the Archives of Neurology.

The study is promising but has limitations, said Dr. Ralph Nixon, director of the NYU Center of Excellence on Brain Aging.

The people in the study already had Alzheimer's, so more research is needed to determine if the test is sensitive and specific enough to be used in people with symptoms such as mild cognitive impairment, a risk factor for Alzheimer's.

Diagnosing Alzheimer's disease is typically done through a clinical examination with a neurologist. Neuroimaging tests are done to rule out other conditions causing the mental declines, such as stroke or brain tumors, Nixon said.

Other methods include a spinal tap or specialized MRIs that can detect amyloid protein, but these are not typically available outside of large metropolitan hospitals or as part of medical studies, O'Bryant noted.

"The real major bottleneck in the field is not so much to detect Alzheimer's, which we can do reasonably well once it has progressed, but to detect the earliest signs of the disease, or to be able to distinguish subtle memory impairment that is related to Alzheimer's from other causes of mild memory impairment," Nixon said.

Currently, several medications can help treat the symptoms of memory loss, but none do anything about the underlying causes of the disease, Nixon said.

"The purpose of the biomarkers is to find a way to identify those changes that happen at the very early stage, so that we can nip it in the bud before things get so advanced in the brain; that's [when] it's very difficult to find a medication to reverse it," Nixon said.

Researchers developed the blood test in conjunction with Rules-Based Medicine in Austin, Texas. It has applied for a patent, O'Bryant said.

In a second study from the same journal, researchers from University of Virginia Health System conducted an 18-month trial to test the safety of pioglitazone (Actos), a diabetes drug, for use in Alzheimer's patients.

Though the drug did not improve Alzheimer's symptoms, there were few side effects, according to the study.

Researchers stressed the trial involved only 25 patients and was designed only to test safety, not efficacy, researchers stressed. The next step will be larger trials to test effectiveness.

"There is a lot of encouraging preclinical data that the pathways and the mechanisms this drug would be targeting are highly relevant to the development of Alzheimer's disease," said Nixon, who was not involved in the research. "There is a quite strong rationale for looking at drugs with this type of action."

The study was funded by the National Institutes of Health/National Institute on Aging.

More information

The National Institute on Aging has more on Alzheimer's.

SOURCES: Sid O'Bryant, Ph.D., director, research, Rural Institute at Texas Tech University Health Sciences Center, Lubbock, Texas; Ralph Nixon, M.D., Ph.D., professor, departments of psychiatry and cell biology, NYU Langone Medical Center, and director, NYU Center of Excellence on Brain Aging, New York City; September 2010 Archives of Neurology


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Biomarkers Could Spot Alzheimers Disease Early, Studies Suggest
2. Hydrophobic proteins: Potential biomarkers for colorectal cancer
3. UAB researchers find 4 biomarkers important in colorectal cancer treatment prognosis
4. BATTLE links potential biomarkers to drugs for lung cancer
5. UAB researchers find 4 biomarkers important in colerectal cancer treatment prognosis
6. More Reliable Biomarkers Needed for Early Detection of Liver Cancer
7. Reliable biomarkers needed for early detection of liver cancer
8. Personalizing cancer: Creating biomarkers from tumor DNA
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. JCI online early table of contents: Sept. 13, 2010
11. Early prostate cancer detection, screening: No benefit for men with low baseline PSA value
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biomarkers May Aid in Early Diagnosis of Alzheimer's
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility ... the armpits, the M+D Crutch evenly distributes body weight from the elbow to the ... when using the crutches than with other crutches. , Co-founders Max and Liliana Younger ...
(Date:4/29/2016)... ... ... is the deadliest type of skin cancer. Although only about 1 percent of skin cancer ... than 10,000 people are expected to die of melanoma this year. The risk increases with ... the most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may ...
(Date:4/29/2016)... Beverly Hills, CA (PRWEB) , ... April 29, 2016 , ... ... distributor of devices and products for the head and neck/ear, nose and throat specialty, ... Safety Device , The KOTLER NASAL AIRWAY™ is a newly patented safety ...
(Date:4/29/2016)... Jupiter, FL (PRWEB) , ... April 29, 2016 ... ... it will feature Grassland Dairy Products, Inc. in an upcoming episode, airing third ... than a century of churning cream into butter, Grassland Dairy Products, located in ...
(Date:4/29/2016)... ... April 29, 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) ... Daniel A. Potter -- are proud of the recent release of their 2014 in ... SART published the latest verified data for 375 U.S. member clinics. *Preliminary ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 ... Financier Sanofi, leader mondial ... ses résultats pour le premier trimestre ... Jérôme Contamine, commente les résultats du ... perspectives pour le reste de l,année. ...
(Date:4/28/2016)... 2016 Research and Markets has ... Products Market 2016-2020" report to their offering. ... The global plastic surgery products market is expected ... period 2016-2020. , ,The growing adoption of laser in ... of the market. Lasers are used to treat a ...
(Date:4/28/2016)... , Net Sales of $1.90 billion represent ... prior year period, and an increase of 1.2% on an ... for the first quarter were $0.52 reported, a decrease of ... increase of 29.9% over the prior year period , ... for 2016 Zimmer Biomet Holdings, Inc. (NYSE and ...
Breaking Medicine Technology: